Chemotherapy Clinical Trials in Beijing
13 recruitingBeijing, China
Showing 1–13 of 13 trials
Recruiting
Phase 2
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)+2 more
AstraZeneca257 enrolled95 locationsNCT06535607
Recruiting
Phase 2
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors
Colorectal, CancerPancreatic CancerGastrointestinal Neoplasms+2 more
Peking University People's Hospital220 enrolled1 locationNCT07586813
Recruiting
Phase 2
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors
Breast CancerGynecologic CancersOvarian Cancer+7 more
Peking University People's Hospital220 enrolled1 locationNCT07586826
Recruiting
Phase 2
Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients
Solid TumorsAdolescentChemotherapy Induced Thrombocytopenia+2 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences50 enrolled1 locationNCT07043894
Recruiting
Phase 2
Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors
Solid TumorsChemotherapy-induced NeutropeniaAdolescent+1 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences132 enrolled1 locationNCT06926751
Recruiting
Phase 3
Study on the Efficacy and Safety of Mecobalamin in Preventing Taxane-related Peripheral Neuropathy
Peripheral Neuropathy Due to ChemotherapyPeripheral Neuropathy, Chemotherapy-induced
Qinghai Red Cross Hospital326 enrolled4 locationsNCT07423390
Recruiting
Phase 3
Neoadjuvant Treatment Modalities in Esophageal Cancer
Esophageal CancerSurgeryChemotherapy Effect+4 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences2,000 enrolled1 locationNCT04821843
Recruiting
Phase 3
Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer
Esophagus CancerChemotherapy EffectTargeted Therapy+3 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences2,000 enrolled5 locationsNCT04821778
Recruiting
Phase 3
GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer
Chemotherapy-induced Peripheral Neuropathy (CIPN)
Qilu Pharmaceutical Co., Ltd.352 enrolled1 locationNCT06994507
Recruiting
Quantitative Nodal Burden as a Determinant Identifying Ampullary Adenocarcinoma Patients Benefiting From Adjuvant Chemotherapy
Chemotherapy EffectAmpullary Adenoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences300 enrolled1 locationNCT06435767
Recruiting
Phase 2
Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients
Esophageal CancerChemotherapyImmunotherapy+2 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences55 enrolled1 locationNCT06429839
Recruiting
Phase 2
Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma
Esophageal CancerChemotherapyImmunotherapy+2 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences53 enrolled1 locationNCT06410651
Recruiting
Not Applicable
COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research
Lung CancerChemotherapyImmune Checkpoint Inhibitor+3 more
Peking Union Medical College Hospital1,224 enrolled1 locationNCT06168032